An interventional study of Cornus mas lyophilisate and Placebo in Healthy, sponsored by Wroclaw Medical University. Completed at 1 site in Poland. Open to male participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Wroclaw Medical University · Not applicable, Interventional, and Basic science
Growing body of evidence indicates favorable effects of Cornus mas (Cornelian cherry) supplements on cardiometabolic risk, including the improvement of HDL and glycemic indices, in line with vascular benefits. Experimental data feature bioactives from Cornelian cherry as potential modulators of vascular function and blood pressure, plausibly via endothelial nitric oxide-related pathways, with possible downstream effects on autonomic reflex control; nevertheless, such links in humans remain poorly explored to date, especially in terms of endurance training and hypoxia tolerance.
In this cross-over, placebo-controlled study, a group of healthy amateur long-distance runners underwent two stages of a four-week dietary intervention (separated by four weeks of washout period), receiving Cornelian cherry lyophilisate or placebo. Each supplementation stage was accompanied by the comprehensive evaluation of the cardio-respiratory parameters and endothelial function.
Wroclaw Medical University is the lead sponsor of 93 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Cornus mas lyophilisate
Dietary Supplement: Placebo
Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.
Participants receiving a starch- and sugar-based placebo for 4 weeks.
Systemic vascular resistance
Resting systemic vascular resistance, evaluated non-invasively with a finger cuff-based device.
Time frame: From the beginning to the end of a supplementation period at 4 weeks.
Office blood pressure values (mean, systolic, diastolic)
Resting arterial blood pressure values (mean, systolic, diastolic), measured continuously with a non-invasive, finger cuff-based device.
Time frame: From the beginning to the end of a supplementation period at 4 weeks.
Peripheral chemoreflex sensitivity
Peripheral chemoreflex sensitivity, measured with the transient hypoxia test.
Time frame: From the beginning to the end of a supplementation period at 4 weeks.
eNOS expression
Endothelial nitric oxide synthase expression, evaluated in the peripheral blood samples.
Time frame: From the beginning to the end of a supplementation period at 4 weeks.
Plan to share: No — This is a small trial which includes solely healthy volunteers. Therefore, data will not be shared at this instance.
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wroclaw Medical University